15 results on '"Pan, Hubert"'
Search Results
2. The Radiation Oncology Job Market: The Economics and Policy of Workforce Regulation.
- Author
-
Falit, Benjamin P., Pan, Hubert Y., Smith, Benjamin D., Alexander, Brian M., and Zietman, Anthony L.
- Subjects
- *
PHYSICIANS , *ONCOLOGISTS , *PROFESSIONAL corporations , *HOSPITAL administrators , *RADIOTHERAPY - Abstract
Examinations of the US radiation oncology workforce offer inconsistent conclusions, but recent data raise significant concerns about an oversupply of physicians. Despite these concerns, residency slots continue to expand at an unprecedented pace. Employed radiation oncologists and professional corporations with weak contracts or loose ties to hospital administrators would be expected to suffer the greatest harm from an oversupply. The reduced cost of labor, however, would be expected to increase profitability for equipment owners, technology vendors, and entrenched professional groups. Policymakers must recognize that the number of practicing radiation oncologists is a poor surrogate for clinical capacity. There is likely to be significant opportunity to augment capacity without increasing the number of radiation oncologists by improving clinic efficiency and offering targeted incentives for geographic redistribution. Payment policy changes significantly threaten radiation oncologists' income, which may encourage physicians to care for greater patient loads, thereby obviating more personnel. Furthermore, the implementation of alternative payment models such as Medicare's Oncology Care Model threatens to decrease both the utilization and price of radiation therapy by turning referring providers into cost-conscious consumers. Medicare funds the vast majority of graduate medical education, but the extent to which the expansion in radiation oncology residency slots has been externally funded is unclear. Excess physician capacity carries a significant risk of harm to society by suboptimally allocating intellectual resources and creating comparative shortages in other, more needed disciplines. There are practical concerns associated with a market-based solution in which medical students self-regulate according to job availability, but antitrust law would likely forbid collaborative self-regulation that purports to restrict supply. Because Congress is unlikely to create one central body to govern residency controls for all specialties, we recommend better reporting of program-specific employment metrics and careful, intellectually honest re-evaluation of existing Accreditation Council for Graduate Medical Education accreditation standards. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Supply and Demand for Radiation Oncology in the United States: Updated Projections for 2015 to 2025.
- Author
-
Pan, Hubert Y., Haffty, Bruce G., Falit, Benjamin P., Buchholz, Thomas A., Wilson, Lynn D., Hahn, Stephen M., and Smith, Benjamin D.
- Subjects
- *
CANCER radiotherapy , *SUPPLY & demand , *EPIDEMIOLOGY , *COMPUTER simulation , *FORECASTING , *MEDICAL needs assessment , *UTILIZATION review (Medical care) , *NEEDS assessment , *ONCOLOGY , *RADIOTHERAPY , *TUMORS , *DISEASE incidence , *STATISTICAL models - Abstract
Purpose: Prior studies have forecasted demand for radiation therapy to grow 10 times faster than the supply between 2010 and 2020. We updated these projections for 2015 to 2025 to determine whether this imbalance persists and to assess the accuracy of prior projections.Methods and Materials: The demand for radiation therapy between 2015 and 2025 was estimated by combining current radiation utilization rates determined by the Surveillance, Epidemiology, and End Results data with population projections provided by the US Census Bureau. The supply of radiation oncologists was forecast by using workforce demographics and full-time equivalent (FTE) status provided by the American Society for Radiation Oncology (ASTRO), current resident class sizes, and expected survival per life tables from the US Centers for Disease Control.Results: Between 2015 and 2025, the annual total number of patients receiving radiation therapy during their initial treatment course is expected to increase by 19%, from 490,000 to 580,000. Assuming a graduating resident class size of 200, the number of FTE physicians is expected to increase by 27%, from 3903 to 4965. In comparison with prior projections, the new projected demand for radiation therapy in 2020 dropped by 24,000 cases (a 4% relative decline). This decrease is attributable to an overall reduction in the use of radiation to treat cancer, from 28% of all newly diagnosed cancers in the prior projections down to 26% for the new projections. By contrast, the new projected supply of radiation oncologists in 2020 increased by 275 FTEs in comparison with the prior projection for 2020 (a 7% relative increase), attributable to rising residency class sizes.Conclusion: The supply of radiation oncologists is expected to grow more quickly than the demand for radiation therapy from 2015 to 2025. Further research is needed to determine whether this is an appropriate correction or will result in excess capacity. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Prognostic Factors and Patterns of Relapse in Ewing Sarcoma Patients Treated With Chemotherapy and R0 Resection.
- Author
-
Pan, Hubert Y., Morani, Ajaykumar, Wang, Wei-Lien, Hess, Kenneth R., Paulino, Arnold C., Ludwig, Joseph A., Lin, Patrick P., Daw, Najat C., and Mahajan, Anita
- Subjects
- *
BONE cancer , *BONE cancer treatment , *SARCOMA , *CANCER chemotherapy , *SURGICAL excision , *MEDICAL records , *DIAGNOSIS , *PROGNOSIS - Abstract
Purpose To identify prognostic factors and patterns of relapse for patients with Ewing sarcoma who underwent chemotherapy and R0 resection without radiation therapy (RT). Methods and Materials We reviewed the medical records of patients who underwent surgical resection at our institution between 2000 and 2013 for an initial diagnosis of Ewing sarcoma. The associations of demographic and clinical factors with local control (LC) and patient outcome were determined by Cox regression. Time to events was measured from the time of surgery. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Results A total of 66 patients (median age 19 years, range 4-55 years) met the study criteria. The median follow-up was 5.6 years for living patients. In 43 patients (65%) for whom imaging studies were available, the median tumor volume reduction was 73%, and at least partial response by Response Evaluation Criteria in Solid Tumors was achieved in 17 patients (40%). At 5 years, LC was 78%, progression-free survival (PFS) was 59%, and overall survival (OS) was 65%. Poor histologic response (necrosis ≤95%) was an independent predictor of LC (hazard ratio [HR] 6.8, P =.004), PFS (HR 5.2, P =.008), and OS (HR 5.0, P =.008). Metastasis on presentation was also an independent predictor of LC (HR 6.3, P =.011), PFS (HR 6.8, P =.002), and OS (HR 6.7, P =.002). Radiologic partial response was a predictor of PFS (HR 0.26, P =.012), and postchemotherapy tumor volume was associated with OS (HR 1.06, P =.015). All deaths were preceded by distant relapse. Of the 8 initial local-only relapses, 5 (63%) were soon followed by distant relapse. Predictors of poor postrecurrence survival were time to recurrence <1 year (HR 11.5, P =.002) and simultaneous local and distant relapse (HR 16.8, P =.001). Conclusions Histologic and radiologic response to chemotherapy were independent predictors of outcome. Additional study is needed to determine the role of adjuvant radiation therapy for patients who have poor histologic response after R0 resection. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Incidence and Predictive Factors of Pain Flare After Spine Stereotactic Body Radiation Therapy: Secondary Analysis of Phase 1/2 Trials.
- Author
-
Pan, Hubert Y., Allen, Pamela K., Wang, Xin S., Chang, Eric L., Rhines, Laurence D., Tatsui, Claudio E., Amini, Behrang, Wang, Xin A., Tannir, Nizar M., Brown, Paul D., and Ghia, Amol J.
- Subjects
- *
DISEASE incidence , *PAIN management , *STEREOTACTIC radiotherapy , *MEDICAL records , *FOLLOW-up studies (Medicine) , *HEALTH surveys - Abstract
Purpose/Objective(s) To perform a secondary analysis of institutional prospective spine stereotactic body radiation therapy (SBRT) trials to investigate posttreatment acute pain flare. Methods and Materials Medical records for enrolled patients were reviewed. Study protocol included baseline and follow-up surveys with pain assessment by Brief Pain Inventory and documentation of pain medications. Patients were considered evaluable for pain flare if clinical note or follow-up survey was completed within 2 weeks of SBRT. Pain flare was defined as a clinical note indicating increased pain at the treated site or survey showing a 2-point increase in worst pain score, a 25% increase in analgesic intake, or the initiation of steroids. Binary logistic regression was used to determine predictive factors for pain flare occurrence. Results Of the 210 enrolled patients, 195 (93%) were evaluable for pain flare, including 172 (88%) clinically, 135 (69%) by survey, and 112 (57%) by both methods. Of evaluable patients, 61 (31%) had undergone prior surgery, 57 (29%) had received prior radiation, and 34 (17%) took steroids during treatment, mostly for prior conditions. Pain flare was observed in 44 patients (23%). Median time to pain flare was 5 days (range, 0-20 days) after the start of treatment. On multivariate analysis, the only independent factor associated with pain flare was the number of treatment fractions (odds ratio = 0.66, P =.004). Age, sex, performance status, spine location, number of treated vertebrae, prior radiation, prior surgery, primary tumor histology, baseline pain score, and steroid use were not significant. Conclusions Acute pain flare after spine SBRT is a relatively common event, for which patients should be counseled. Additional study is needed to determine whether prophylactic or symptomatic intervention is preferred. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. A survey of stereotactic body radiotherapy use in the United States.
- Author
-
Pan, Hubert, Simpson, Daniel R., Mell, Loren K., Mundt, Arno J., and Lawson, Joshua D.
- Subjects
- *
RADIOTHERAPY , *CANCER treatment , *CANCER patients , *RADIATION doses , *MEDICAL radiology - Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) is a technique used to deliver high, ablative doses of radiation in a limited number of fractions to ≥1 extracranial target(s). To the authors' knowledge, the prevalence of SBRT use among radiation oncologists in the United States is unknown. METHODS: A random sample of 1600 American radiation oncologists was surveyed via e-mail and facsimile (fax) regarding SBRT usage, including year of adoption, motivations, disease sites treated, and common prescriptions used. RESULTS: Of 1373 contactable physicians, 551 responses (40.1%) were received. The percentage of physicians using SBRT was 63.9% (95% confidence interval, 60%-68%), of whom nearly half adopted it in 2008 or later. The most commonly cited reasons for adopting SBRT were to allow the delivery of higher than conventional radiation doses (90.3%) and to allow retreatment (73.9%) in select patients. Academic physicians were more likely to report research as a motivation for SBRT adoption, whereas physicians in private practice were more likely to list competitive reasons. Among SBRT users, the most common disease sites treated were lung (89.3%), spine (67.5%), and liver (54.5%) tumors. Overall, 76.0% of current SBRT users planned to increase their use, whereas 66.5% of nonusers planned to adopt the technology in the future. CONCLUSIONS: SBRT has rapidly become a widely adopted treatment approach among American radiation oncologists. Further research and prospective trials are necessary to assess the benefits and risks of this novel technology. Cancer 2011;. © 2011 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. Influence of Geography on Prostate Cancer Treatment.
- Author
-
Tang, Chad, Lei, Xiudong, Smith, Grace L., Pan, Hubert Y., Hoffman, Karen E., Kumar, Rachit, Chapin, Brian F., Shih, Ya-Chen Tina, Frank, Steven J., and Smith, Benjamin D.
- Subjects
- *
CANCER treatment , *MEDICAL societies , *PROTON therapy , *PROSTATE cancer patients , *RADIOTHERAPY , *PROSTATE cancer - Abstract
Purpose: Several definitive treatment options are available for prostate cancer, but geographic access to those options is not uniform. We created maps illustrating provider practice patterns relation to patients and assessed the influence of distance to treatment receipt.Methods and Materials: The patient cohort was created by searching the National Medicare Database for patients diagnosed and treated for prostate cancer from 2011 to 2014. The provider cohort was created by querying the American Medical Association Physician Masterfile to identify physicians who had treated patients with prostatectomy, intensity modulated radiation therapy (IMRT), brachytherapy, stereotactic body radiation therapy (SBRT), or proton therapy. Maps detailing the location of providers were created for each modality. Multivariate multinomial logistic regressions were used to assess the association between patient-provider distance and probability of treatment.Results: Cohorts consisted of 89,902 patients treated by 5518 physicians. Substantial numbers of providers practicing established modalities (IMRT, prostatectomy, and brachytherapy) were noted in major urban centers, whereas provider numbers were reduced in rural areas, most notably for brachytherapy. Ninety percent of prostate cancer patients lived within 35.1, 28.9, and 55.6 miles of a practitioner of prostatectomy, IMRT, and brachytherapy, respectively. Practitioners of emerging modalities (SBRT and proton therapy) were predominantly concentrated in urban locations, with 90% of patients living within 128 miles (SBRT) and 374.5 miles (proton). Greater distance was associated with decreased probability of treatment (IMRT -3.8% per 10 miles; prostatectomy -2.1%; brachytherapy -2%; proton therapy -1.6%; and SBRT -1.1%).Conclusions: Geographic disparities were noted for analyzed treatment modalities, and these disparities influenced delivery. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Implementing an Electronic Data Capture System to Improve Clinical Workflow in a Large Academic Radiation Oncology Practice.
- Author
-
Pasalic, Dario, Reddy, Jay P., Edwards, Timothy, Pan, Hubert Y., and Smith, Benjamin D.
- Subjects
- *
ELECTRONIC data processing , *ONCOLOGY , *COMPUTERS in education , *INFORMATION processing , *INFORMATION science - Abstract
Purpose: To describe the feasibility and benefits of implementing a custom radiation oncology electronic data capture (EDC) system in a large academic radiation oncology practice. Patients and Methods: A Web-based point-and-click EDC known as Brocade was internally developed and implemented systemwide in 2016. Brocade captures key data elements, such as stage, histology, and patient and treatment characteristics; links this information to radiation dose data extracted from the record and verify system; and creates clinical notes that are automatically exported to the hospital electronic health record. We report the number of unique radiation episodes captured by Brocade in its first full year of implementation and describe the notes generated, toxicities captured, compliance with staging and quality assurance, and time of day in which documentation occurred with Brocade versus our prior human transcription system. Results: A median of 756 radiation episodes per month was captured for a total of 9,283 unique episodes captured in the first full year of implementation. The most common notes were for on-treatment visits (29,913) and simulations (13,220). Stage was captured for 92.2% of Brocade episodes (8,513 of 9,236) versus 29.7% of courses pre-Brocade (3,025 of 10,170; P <.001). Quality assurance was documented for 96.3% of completed courses (7,601 of 7,892). The most common grade ≥1 toxicities were pain (10,031), fatigue (7,490), and dermatitis (6,172). Brocade implementation was associated with a reduction in off-hours documentation and increase in the proportion of documentation created between 8:00 am and 12:00 pm. Conclusion: Brocade is a reliable Web-based EDC tool that improves clinical documentation without detracting from clinical workflow. Moreover, Brocade has the advantage of capturing data in a structured manner that facilitates real-time analytics and outcome reporting. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Comparative Costs and Toxicities of Brachytherapy and Intensity Modulated Radiation among Younger Men with Prostate Cancer.
- Author
-
Tang, Chad, Jiang, Jing, Pan, Hubert, Anscher, Mitchell S., Smith, Benjamin D., and Frank, Steven J.
- Subjects
- *
PROSTATE cancer patients , *RADIOISOTOPE brachytherapy , *GENITOURINARY diseases , *IMPOTENCE , *CANCER treatment - Published
- 2018
- Full Text
- View/download PDF
10. (P51) Enriching an Electronic Health Record With a Prospective Electronic Data Capture System to Improve Workflow and Research.
- Author
-
Pasalic, Dario, Edwards, Timothy, Pan, Hubert, Herman, Joseph, and Smith, Benjamin D.
- Subjects
- *
ELECTRONIC health records , *ELECTRONIC records , *COMPUTERS in the health care industry , *WORKFLOW management , *MEDICAL research - Published
- 2018
- Full Text
- View/download PDF
11. Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery.
- Author
-
Jensen, Garrett, Chad Tang, Hess, Kenneth R., Bishop, Andrew J., Pan, Hubert Y., Jing Li, Yang, James N., Tannir, Nizar M., Amini, Behrang, Tatsui, Claudio, Rhines, Laurence, Brown, Paul D., and Ghia, Amol J.
- Subjects
- *
BONE metastasis , *MULTIVARIATE analysis , *STEREOTACTIC radiosurgery , *CLINICAL trials , *SUBGROUP growth - Abstract
Purpose: We sought to validate the Prognostic Index for Spinal Metastases (PRISM), a scoring system that stratifies patients into subgroups by overall survival. Methods and materials: The PRISM was previously created from multivariate Cox regression with patients enrolled in prospective single institution trials of stereotactic spine radiosurgery (SSRS) for spinal metastasis. We assess model calibration and discrimination within a validation cohort of patients treated off-trial with SSRS for metastatic disease at the same institution. Results: The training and validation cohorts consisted of 205 and 249 patients respectively. Similar survival trends were shown in the 4 PRISM. Survival was significantly different between PRISM subgroups (P<0.0001). C-index for the validation cohort was 0.68 after stratification into subgroups. Conclusions: We internally validated the PRISM with patients treated off-protocol, demonstrating that it can distinguish subgroups by survival, which will be useful for individualizing treatment of spinal metastases and stratifying patients for clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
12. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.
- Author
-
Sperduto, Paul W., Yang, T. Jonathan, Beal, Kathryn, Pan, Hubert, Brown, Paul D., Bangdiwala, Ananta, Shanley, Ryan, Yeh, Norman, Gaspar, Laurie E., Braunstein, Steve, Sneed, Penny, Boyle, John, Kirkpatrick, John P., Mak, Kimberley S., Shih, Helen A., Engelman, Alex, Roberge, David, Arvold, Nils D., Alexander, Brian, and Awad, Mark M.
- Subjects
- *
PROTEIN-tyrosine kinases , *PROTEIN kinases , *ADENOCARCINOMA , *CANCER treatment , *METASTASIS , *PATIENTS - Abstract
Purpose: Lung cancer remains the most common cause of both cancer mortality and brain metastases (BM). The purpose of this study was to assess the effect of gene alterations and tyrosine kinase inhibition (TKI) on median survival (MS) and cause of death (CoD) in patients with BM from lung adenocarcinoma (L-adeno).Methods: A multi-institutional retrospective database of patients with L-adeno and newly diagnosed BM between 2006 and 2014 was created. Demographics, gene alterations, treatment, MS, and CoD were analyzed. The treatment patterns and outcomes were compared with those in prior trials.Results: Of 1521 L-adeno patients, 816 (54%) had known alteration status. The gene alteration rates were 29%, 10%, and 26% for EGFR, ALK, and KRAS, respectively. The time from primary diagnosis to BM for EGFR-/+ was 10/15 months (P=.02) and for ALK-/+ was 10/20 months (P<.01), respectively. The MS for the group overall (n=1521) was 15 months. The MS from first treatment for BM for EGFR and ALK-, EGFR+, ALK+ were 14, 23 (P<.01), and 45 (P<.0001) months, respectively. The MS after BM for EGFR+ patients who did/did not receive TKI before BM was 17/30 months (P<.01), respectively, but the risk of death was not statistically different between TKI-naïve patients who did/did not receive TKI after the diagnosis of BM (EGFR/ALK hazard ratios: 1.06 [P=.84]/1.60 [P=.45], respectively). The CoD was nonneurologic in 82% of patients with known CoD.Conclusion: EGFR and ALK gene alterations are associated with delayed onset of BM and longer MS relative to patients without these alterations. The CoD was overwhelmingly nonneurologic in patients with known CoD. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
13. Spine Stereotactic Radiosurgery for Patients with Metastatic Thyroid Cancer: Secondary Analysis of Phase I/II Trials.
- Author
-
Bernstein, Michael B., Chang, Eric L., Amini, Behrang, Pan, Hubert, Cabanillas, Maria, Wang, Xin A., Allen, Pamela K., Rhines, Laurence D., Tatsui, Claudio, Li, Jing, Brown, Paul D., and Ghia, Amol J.
- Subjects
- *
STEREOTACTIC radiosurgery , *STEREOTACTIC radiotherapy , *THYROID cancer treatment , *THYROID cancer patients , *KAPLAN-Meier estimator - Abstract
Background: Metastatic deposits to the spine in thyroid cancer patients represent the most common site of bone involvement and can contribute to pain, neurologic deficits, and death. This study sought to determine the efficacy and safety of spine stereotactic radiosurgery (SSRS) for thyroid cancer patients. Methods: Thyroid cancer patients with spine metastases were selected and analyzed from a cohort of patients who were prospectively enrolled in two single-institution Phase I/II studies. SSRS was delivered in single or multi-fraction schedules. Dose regimens ranged from 16-18 Gy in one fraction to 27-30 Gy in three to five fractions. Toxicity was graded according to the NCI-CTC toxicity scale. Local control was determined by serial post-treatment magnetic resonance imaging scans showing no evidence of progressive disease. Patients were followed until date of death or date of last known visit for survival analyses. Local control and overall survival rates were carried out using Kaplan-Meier estimates. The log-rank test was used to assess the equality of the survivor function across groups. A p-value of ≤0.05 was considered to be statistically significant. Results: A total of 27 spine lesions were treated in 23 patients over a six-year period. Median follow-up was 28.9 months (range 5-93 months). Local control was 88% at two years and 79% at three years. In patients with progressive disease following conventional radiation therapy, local control for salvage SSRS remained at 88% at three years. Patients requiring upfront surgical intervention and treated with adjuvant SSRS achieved sustained control rates of 86% at three years. Overall survival rates were 85% and 67% at one and two years, respectively. In patients classified with oligoprogression and controlled extra-spinal disease, overall survival was significantly higher than those with evidence of systemic progression (81% vs. 45% at two years; p = 0.01). Univariate analysis did not show significant correlations between local control and age, systemic disease status, prior 131I therapy, SSRS fraction regimen, spine location, histological subtype, or time from initial diagnosis to evidence of spinal metastasis. No patient experienced any grade 3-5 toxicity. Pain flare was reported in 30% of patients, with only three patients (13%) requiring narcotics or short-course steroids. There was no evidence of vertebral body fracture in any patient that achieved local control in the treated area. Conclusions: SSRS for thyroid metastases as a primary or adjuvant/salvage therapy is well tolerated and yields high rates of local control. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Creation of a Prognostic Index for Spine Metastasis to Stratify Survival in Patients Treated With Spinal Stereotactic Radiosurgery: Secondary Analysis of Mature Prospective Trials.
- Author
-
Tang, Chad, Hess, Kenneth, Bishop, Andrew J., Pan, Hubert Y., Christensen, Eva N., Yang, James N., Tannir, Nizar, Amini, Behrang, Tatsui, Claudio, Rhines, Laurence, Brown, Paul, and Ghia, Amol
- Subjects
- *
CANCER radiotherapy , *STEREOTACTIC radiosurgery , *CANCER prognosis , *CLINICAL trials , *MULTIVARIATE analysis , *LONGITUDINAL method , *CANCER treatment ,SPINE cancer - Abstract
Purpose There exists uncertainty in the prognosis of patients following spinal metastasis treatment. We sought to create a scoring system that stratifies patients based on overall survival. Methods and Materials Patients enrolled in 2 prospective trials investigating stereotactic spine radiation surgery (SSRS) for spinal metastasis with ≥3-year follow-up were analyzed. A multivariate Cox regression model was used to create a survival model. Pretreatment variables included were race, sex, age, performance status, tumor histology, extent of vertebrae involvement, previous therapy at the SSRS site, disease burden, and timing of diagnosis and metastasis. Four survival groups were generated based on the model-derived survival score. Results Median follow-up in the 206 patients included in this analysis was 70 months (range: 37-133 months). Seven variables were selected: female sex (hazard ratio [HR] = 0.7, P =.02), Karnofsky performance score (HR = 0.8 per 10-point increase above 60, P =.007), previous surgery at the SSRS site (HR = 0.7, P =.02), previous radiation at the SSRS site (HR = 1.8, P =.001), the SSRS site as the only site of metastatic disease (HR = 0.5, P =.01), number of organ systems involved outside of bone (HR = 1.4 per involved system, P <.001), and >5 year interval from initial diagnosis to detection of spine metastasis (HR = 0.5, P <.001). The median survival among all patients was 25.5 months and was significantly different among survival groups (in group 1 [excellent prognosis], median survival was not reached; group 2 reached 32.4 months; group 3 reached 22.2 months; and group 4 [poor prognosis] reached 9.1 months; P <.001). Pretreatment symptom burden was significantly higher in the patient group with poor survival than in the group with excellent survival (all metrics, P <.05). Conclusions We developed the prognostic index for spinal metastases (PRISM) model, a new model that identified patient subgroups with poor and excellent prognoses. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis.
- Author
-
Chance, William W., Rice, David C., Allen, Pamela K., Tsao, Anne S., Fontanilla, Hiral P., Liao, Zhongxing, Chang, Joe Y., Tang, Chad, Pan, Hubert Y., Welsh, James W., Mehran, Reza J., and Gomez, Daniel R.
- Subjects
- *
RADIOTHERAPY , *PNEUMONECTOMY , *MESOTHELIOMA , *TREATMENT effectiveness , *THORACIC duct , *HEALTH outcome assessment , *COMPARATIVE studies , *PATIENTS , *DISEASES - Abstract
Purpose To investigate safety, efficacy, and recurrence after hemithoracic intensity modulated radiation therapy after pleurectomy/decortication (PD-IMRT) and after extrapleural pneumonectomy (EPP-IMRT). Methods and Materials In 2009-2013, 24 patients with mesothelioma underwent PD-IMRT to the involved hemithorax to a dose of 45 Gy, with an optional integrated boost; 22 also received chemotherapy. Toxicity was scored with the Common Terminology Criteria for Adverse Events v4.0. Pulmonary function was compared at baseline, after surgery, and after IMRT. Kaplan-Meier analysis was used to calculate overall survival (OS), progression-free survival (PFS), time to locoregional failure, and time to distant metastasis. Failures were in-field, marginal, or out of field. Outcomes were compared with those of 24 patients, matched for age, nodal status, performance status, and chemotherapy, who had received EPP-IMRT. Results Median follow-up time was 12.2 months. Grade 3 toxicity rates were 8% skin and 8% pulmonary. Pulmonary function declined from baseline to after surgery (by 21% for forced vital capacity, 16% for forced expiratory volume in 1 second, and 19% for lung diffusion of carbon monoxide [ P for all = .01]) and declined still further after IMRT (by 31% for forced vital capacity [ P =.02], 25% for forced expiratory volume in 1 second [ P =.01], and 30% for lung diffusion of carbon monoxide [ P =.01]). The OS and PFS rates were 76% and 67%, respectively, at 1 year and 56% and 34% at 2 years. Median OS (28.4 vs 14.2 months, P =.04) and median PFS (16.4 vs 8.2 months, P =.01) favored PD-IMRT versus EPP-IMRT. No differences were found in grade 4-5 toxicity (0 of 24 vs 3 of 24, P =.23), median time to locoregional failure (18.7 months vs not reached, P not calculable), or median time to distant metastasis (18.8 vs 11.8 months, P =.12). Conclusions Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication produced little high-grade toxicity but led to progressive declines in pulmonary function; OS and PFS were better in PD-IMRT compared with EPP-IMRT. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.